» Articles » PMID: 21497847

AUA Guideline for the Diagnosis and Treatment of Interstitial Cystitis/bladder Pain Syndrome

Abstract

Purpose: To provide a clinical framework for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome.

Materials And Methods: A systematic review of the literature using the MEDLINE® database (search dates 1/1/83-7/22/09) was conducted to identify peer reviewed publications relevant to the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Insufficient evidence-based data were retrieved regarding diagnosis and, therefore, this portion of the Guideline is based on Clinical Principles and Expert Opinion statements. The review yielded an evidence base of 86 treatment articles after application of inclusion/exclusion criteria. These publications were used to create the majority of the treatment portion of the Guideline. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate) or C (low). Additional treatment information is provided as Clinical Principles and Expert Opinion when insufficient evidence existed. See text and algorithm for definitions, and detailed diagnostic management, and treatment frameworks.

Results: The evidence-based guideline statements are provided for diagnosis and overall management of interstitial cystitis/bladder pain syndrome as well as for various treatments. The panel identified first through sixth line treatments as well as developed guideline statements on treatments that should not be offered.

Conclusions: Interstitial cystitis/bladder pain syndrome is best identified and managed through use of a logical algorithm such as is presented in this Guideline. In the algorithm the panel identifies an overall management strategy for the interstitial cystitis/bladder pain syndrome patient. Diagnosis and treatment methodologies can be expected to change as the evidence base grows in the future.

Citing Articles

Exploring the causal role of pathogen-derived antibodies in major urinary and kidney diseases: Insights from generalized summary data-based Mendelian randomization.

Huang H, Chen B, Feng C, Chen W, Wu D Virulence. 2025; 16(1):2473631.

PMID: 40033947 PMC: 11906112. DOI: 10.1080/21505594.2025.2473631.


Exploring the anti-inflammatory effects of phytochemicals in attenuating interstitial cystitis-a literature review.

Anjum I, Nasir A, Naseer F, Ibrahim A, Rehman B, Bashir F Front Pharmacol. 2025; 16:1483548.

PMID: 39974737 PMC: 11836544. DOI: 10.3389/fphar.2025.1483548.


IC/BPS is not associated with bladder cancer: a nationwide propensity score matched cohort study in Taiwan.

Lee M, Wu H, Chen W, Chen Y World J Urol. 2025; 43(1):123.

PMID: 39953327 DOI: 10.1007/s00345-025-05501-y.


Exploring the therapeutic potential of PACAP in Hunner-type Interstitial Cystitis.

Ke H, Zhu L, Wang Q, Xu K World J Urol. 2025; 43(1):60.

PMID: 39755799 DOI: 10.1007/s00345-024-05429-9.


Chronic Primary Pelvic Pain Syndromes in Women: A Comprehensive Review.

Pinto L, Soutinho M, Coutinho Fernandes M, Taboas M, Leal J, Tome S Cureus. 2025; 16(12):e74918.

PMID: 39742169 PMC: 11688162. DOI: 10.7759/cureus.74918.


References
1.
Rovner E, Propert K, Brensinger C, Wein A, Foy M, Kirkemo A . Treatments used in women with interstitial cystitis: the interstitial cystitis data base (ICDB) study experience. The Interstitial Cystitis Data Base Study Group. Urology. 2000; 56(6):940-5. DOI: 10.1016/s0090-4295(00)00845-1. View

2.
Tincello D, Walker A . Interstitial cystitis in the UK: results of a questionnaire survey of members of the Interstitial Cystitis Support Group. Eur J Obstet Gynecol Reprod Biol. 2004; 118(1):91-5. DOI: 10.1016/j.ejogrb.2004.06.012. View

3.
Greenberg P, Tracy J, Meyer W, Yates T, Diggs C, Warren J . Short interval between symptom onset and medical care as an indication of rapid onset of interstitial cystitis/painful bladder syndrome. BJU Int. 2007; 100(3):599-602. DOI: 10.1111/j.1464-410X.2007.06989.x. View

4.
Hsieh T, Yu K, Lin S . Possible application of Raman microspectroscopy to verify the interstitial cystitis diagnosis after potassium sensitivity test: phenylalanine or tryptophan as a biomarker. Dis Markers. 2007; 23(3):147-52. PMC: 3851605. DOI: 10.1155/2007/705630. View

5.
Shorter B, Lesser M, Moldwin R, Kushner L . Effect of comestibles on symptoms of interstitial cystitis. J Urol. 2007; 178(1):145-52. DOI: 10.1016/j.juro.2007.03.020. View